NCT02381028

Brief Summary

The aim of this small pilot study is to assess the potential effects and risks of applying fresh human milk locally on eczema spots in children with atopic eczema. This is a split body, controlled, randomized and physician blinded pilot study, of children with atopic eczema with two similar contralateral eczema spots having a mother breastfeeding the child or a sibling. Fresh expressed milk and emollient is to be applied on the intervention spot and emollient alone on the control area, three times a day for four weeks. Severity and area of the eczema spots is evaluated weekly, and samples from milk and the spots were analysed weekly with respect to bacterial colonisation.

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
9

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Oct 2008

Typical duration for not_applicable

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 1, 2008

Completed
2.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 1, 2010

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

November 1, 2010

Completed
4.3 years until next milestone

First Submitted

Initial submission to the registry

February 28, 2015

Completed
6 days until next milestone

First Posted

Study publicly available on registry

March 6, 2015

Completed
Last Updated

March 6, 2015

Status Verified

March 1, 2015

Enrollment Period

2.1 years

First QC Date

February 28, 2015

Last Update Submit

March 4, 2015

Conditions

Keywords

Atopic eczemaHuman milkTopical treatmentChildren

Outcome Measures

Primary Outcomes (1)

  • Proportional change in area of the eczema spot from baseline

    The primary outcome was proportional change in area (cm2) of the eczema spot from baseline, as measured by Visitrak™ (Smith \& Nephew), a portable device used to measure the area of wounds.

    four weeks

Secondary Outcomes (1)

  • Transmission of bacteria from mother's milk to eczema spots in the child

    four weeks

Study Arms (2)

Study area

EXPERIMENTAL

Human milk and emollient: Apobase creme® (Actavis Norway AS)

Other: Human milk and emollient: Apobase creme® (Actavis Norway AS)Other: Emollient: Apobase creme® (Actavis Norway AS)

Control area

ACTIVE COMPARATOR

Emollient: Apobase creme® (Actavis Norway AS)

Other: Emollient: Apobase creme® (Actavis Norway AS)

Interventions

Topical application of human milk followed by emollient

Study area

Topical application of emollient

Control areaStudy area

Eligibility Criteria

AgeUp to 6 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)

You may qualify if:

  • Children with atopic eczema according to Hanifin and Rajkas criteria with a mother breastfeeding the child or a sibling.
  • The eczema spots in the treatment and control areas were to be similar in features and extent as well as being localized on contralateral parts of the body.

You may not qualify if:

  • Children were excluded if the severity of the eczema spots indicated need for treatment with antibiotics and/or steroids.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (1)

  • Berents TL, Ronnevig J, Soyland E, Gaustad P, Nylander G, Loland BF. Topical treatment with fresh human milk versus emollient on atopic eczema spots in young children: a small, randomized, split body, controlled, blinded pilot study. BMC Dermatol. 2015 May 4;15:7. doi: 10.1186/s12895-015-0027-9.

MeSH Terms

Conditions

Dermatitis, Atopic

Interventions

Milk, Human

Condition Hierarchy (Ancestors)

Skin Diseases, GeneticGenetic Diseases, InbornCongenital, Hereditary, and Neonatal Diseases and AbnormalitiesDermatitisSkin DiseasesSkin and Connective Tissue DiseasesSkin Diseases, EczematousHypersensitivity, ImmediateHypersensitivityImmune System Diseases

Intervention Hierarchy (Ancestors)

MilkBeveragesDiet, Food, and NutritionPhysiological PhenomenaDairy ProductsFoodFood and Beverages

Study Officials

  • Teresa L Berents, MD

    Oslo University Hospital

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
INVESTIGATOR
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Medical doctor

Study Record Dates

First Submitted

February 28, 2015

First Posted

March 6, 2015

Study Start

October 1, 2008

Primary Completion

November 1, 2010

Study Completion

November 1, 2010

Last Updated

March 6, 2015

Record last verified: 2015-03